Ancylostomiasis medical therapy: Difference between revisions
Jump to navigation
Jump to search
Jose Loyola (talk | contribs) |
Jose Loyola (talk | contribs) |
||
| Line 23: | Line 23: | ||
**'''Children <2 years of age''' | **'''Children <2 years of age''' | ||
***Currently, for the [[treatment]] of young [[infants]], no guidelines are [[available]]. But current [[knowledge]] shows that the [[side effects]] linked to [[benzimidazole]] drugs in young children are likely to be the same as in older [[children]] and [[adults]]. Therefore, for the [[potential]] [[benefit]] of [[physical]] and [[cognitive development]], the [[treatment]] of [[young infants]] could be [[justified]].<ref name="pmid12745139">{{cite journal| author=Montresor A, Awasthi S, Crompton DW| title=Use of benzimidazoles in children younger than 24 months for the treatment of soil-transmitted helminthiasis. | journal=Acta Trop | year= 2003 | volume= 86 | issue= 2-3 | pages= 223-32 | pmid=12745139 | doi=10.1016/s0001-706x(03)00042-1 | pmc=5633076 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12745139 }} </ref> | ***Currently, for the [[treatment]] of young [[infants]], no guidelines are [[available]]. But current [[knowledge]] shows that the [[side effects]] linked to [[benzimidazole]] drugs in young children are likely to be the same as in older [[children]] and [[adults]]. Therefore, for the [[potential]] [[benefit]] of [[physical]] and [[cognitive development]], the [[treatment]] of [[young infants]] could be [[justified]].<ref name="pmid12745139">{{cite journal| author=Montresor A, Awasthi S, Crompton DW| title=Use of benzimidazoles in children younger than 24 months for the treatment of soil-transmitted helminthiasis. | journal=Acta Trop | year= 2003 | volume= 86 | issue= 2-3 | pages= 223-32 | pmid=12745139 | doi=10.1016/s0001-706x(03)00042-1 | pmc=5633076 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12745139 }} </ref> | ||
***Preferred regimen: albendazole 200 mg PO single dose.<ref name="pmid20228435">{{cite journal| author=Bhatia V, Das MK, Kumar P, Arora NK| title=Infantile hookworm disease. | journal=Indian Pediatr | year= 2010 | volume= 47 | issue= 2 | pages= 190-2 | pmid=20228435 | doi=10.1007/s13312-010-0033-2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20228435 }} </ref> | ***Preferred regimen: [[albendazole]] 200 mg PO single dose.<ref name="pmid20228435">{{cite journal| author=Bhatia V, Das MK, Kumar P, Arora NK| title=Infantile hookworm disease. | journal=Indian Pediatr | year= 2010 | volume= 47 | issue= 2 | pages= 190-2 | pmid=20228435 | doi=10.1007/s13312-010-0033-2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20228435 }} </ref> | ||
***Alternative regimen: mebendazole 100 mg PO q12h for 3 days.<ref name="pmid33563313">{{cite journal| author=Umbrello G, Pinzani R, Bandera A, Formenti F, Zavarise G, Arghittu M | display-authors=etal| title=Hookworm infection in infants: a case report and review of literature. | journal=Ital J Pediatr | year= 2021 | volume= 47 | issue= 1 | pages= 26 | pmid=33563313 | doi=10.1186/s13052-021-00981-1 | pmc=7871578 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=33563313 }} </ref> | ***Alternative regimen: [[mebendazole]] 100 mg PO q12h for 3 days.<ref name="pmid33563313">{{cite journal| author=Umbrello G, Pinzani R, Bandera A, Formenti F, Zavarise G, Arghittu M | display-authors=etal| title=Hookworm infection in infants: a case report and review of literature. | journal=Ital J Pediatr | year= 2021 | volume= 47 | issue= 1 | pages= 26 | pmid=33563313 | doi=10.1186/s13052-021-00981-1 | pmc=7871578 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=33563313 }} </ref> | ||
==References== | ==References== | ||
Revision as of 03:20, 9 September 2021
|
Ancylostomiasis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Ancylostomiasis medical therapy On the Web |
|
American Roentgen Ray Society Images of Ancylostomiasis medical therapy |
|
Risk calculators and risk factors for Ancylostomiasis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Anti-helminthic therapies are recommended among patients with ancylostomiasis. Efficacy of treatment varies according to the severity of infection, geographical distribution, and age groups. Multiple blood transfusion, Iron supplements are also be given in severe cases.
Medical Therapy
Anti-helminthic therapies are recommended among patients with ancylostomiasis. Efficacy of treatment varies according to the severity of infection, geographical distribution, and age groups.[1]
- Adult
- For stable uncomplicated cases
- Preferred regimen: albendazole 400 mg PO single dose. If failed to respond it is recommended to administer albendazole 400 mg PO q24 h for 3 days or 800 mg PO as a single dose[2]
- Alternative regimen: mebendazole 100 mg PO q12h for 3 days.[1]
- Alternative regimen: pyrantel pamoate 11mg/kg PO q24h for 3 days (maximum, 1gm per dose)
- For unstable complicated cases
- Albendazole 400 mg PO q24 h for 3 days[2]
- Mebendazole 100 mg PO q24 h for 5 days
- Multiple blood transfusion
- Iron supplements
- For stable uncomplicated cases
- Pediatric
- Children <2 years of age
- Currently, for the treatment of young infants, no guidelines are available. But current knowledge shows that the side effects linked to benzimidazole drugs in young children are likely to be the same as in older children and adults. Therefore, for the potential benefit of physical and cognitive development, the treatment of young infants could be justified.[3]
- Preferred regimen: albendazole 200 mg PO single dose.[4]
- Alternative regimen: mebendazole 100 mg PO q12h for 3 days.[5]
- Children <2 years of age
References
- ↑ 1.0 1.1 Loukas A, Hotez PJ, Diemert D, Yazdanbakhsh M, McCarthy JS, Correa-Oliveira R; et al. (2016). "Hookworm infection". Nat Rev Dis Primers. 2: 16088. doi:10.1038/nrdp.2016.88. PMID 27929101.
- ↑ 2.0 2.1 Ronquillo AC, Puelles LB, Espinoza LP, Sánchez VA, Luis Pinto Valdivia J (2019). "Ancylostoma duodenale as a cause of upper gastrointestinal bleeding: a case report". Braz J Infect Dis. 23 (6): 471–473. doi:10.1016/j.bjid.2019.09.002. PMID 31622567.
- ↑ Montresor A, Awasthi S, Crompton DW (2003). "Use of benzimidazoles in children younger than 24 months for the treatment of soil-transmitted helminthiasis". Acta Trop. 86 (2–3): 223–32. doi:10.1016/s0001-706x(03)00042-1. PMC 5633076. PMID 12745139.
- ↑ Bhatia V, Das MK, Kumar P, Arora NK (2010). "Infantile hookworm disease". Indian Pediatr. 47 (2): 190–2. doi:10.1007/s13312-010-0033-2. PMID 20228435.
- ↑ Umbrello G, Pinzani R, Bandera A, Formenti F, Zavarise G, Arghittu M; et al. (2021). "Hookworm infection in infants: a case report and review of literature". Ital J Pediatr. 47 (1): 26. doi:10.1186/s13052-021-00981-1. PMC 7871578 Check
|pmc=value (help). PMID 33563313 Check|pmid=value (help).